On Tuesday, Beam Therapeutics Inc (NASDAQ: BEAM) was 4.85% up from the session before settling in for the closing price of $24.12. A 52-week range for BEAM has been $20.84 – $49.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 43297.50%. When this article was written, the company’s average yearly earnings per share was at -174.30%. With a float of $72.66 million, this company’s outstanding shares have now reached $81.63 million.
Let’s determine the extent of company efficiency that accounts for 436 employees. In terms of profitability, gross margin is 93.75%, operating margin of -52.25%, and the pretax margin is -40.67%.
Beam Therapeutics Inc (BEAM) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Beam Therapeutics Inc stocks. The insider ownership of Beam Therapeutics Inc is 12.25%, while institutional ownership is 81.95%. The most recent insider transaction that took place on Nov 06 ’24, was worth 1,347,050. In this transaction President of this company sold 51,110 shares at a rate of $26.36, taking the stock ownership to the 109,150 shares. Before that another transaction happened on Oct 14 ’24, when Company’s President sold 51,110 for $26.27, making the entire transaction worth $1,342,752. This insider now owns 160,260 shares in total.
Beam Therapeutics Inc (BEAM) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted 1.73 earnings per share (EPS) during the time that was better than consensus figure (set at -0.71) by 2.44. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -174.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 5.58% growth over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
You can see what Beam Therapeutics Inc (BEAM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.76, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -4.81 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Looking closely at Beam Therapeutics Inc (NASDAQ: BEAM), its last 5-days average volume was 1.29 million, which is a jump from its year-to-date volume of 1.24 million. As of the previous 9 days, the stock’s Stochastic %D was 16.31%. Additionally, its Average True Range was 1.88.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 32.07%, which indicates a significant decrease from 35.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 96.00% in the past 14 days, which was higher than the 68.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.55, while its 200-day Moving Average is $26.80. However, in the short run, Beam Therapeutics Inc’s stock first resistance to watch stands at $25.90. Second resistance stands at $26.50. The third major resistance level sits at $27.62. If the price goes on to break the first support level at $24.18, it is likely to go to the next support level at $23.06. Should the price break the second support level, the third support level stands at $22.46.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
There are 82,806K outstanding shares of the company, which has a market capitalization of 2.09 billion. As of now, sales total 377,710 K while income totals -132,530 K. Its latest quarter income was 14,270 K while its last quarter net income were -96,670 K.
